Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
EMD Serono Research & Development Institute, Inc.
With
Merck KGaA, Darmstadt, Germany
Age
50–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
RRMS subjects who have been treated with interferon beta 1a SC 44 micro-gram thrice a week and dimethyl fumarate in inpatient or outpatient settings during the period from January 1, 2015 to December 31, 2015.
Subjects with at least one year of laboratory values post-index date to analyze lymphocyte counts, and CD4 and CD8 counts. The date of first blood draw for laboratory tests after January 1, 2015 will be defined as the subject's index date.
You may not be if
\- Subjects who have been on treatment for less than 1 year after their index date.
Clareo Health | Retrospective Study to Determine Effect of Rebif and Tecfidera on Infections and Lymphocytes
